Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Daewoong Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Moderate to Severe Glabellar Line

Treatments: Drug: Generic equivalent of Clostridium Botulinum A Toxin; Drug: Botox (Clostridium Botulinum A Toxin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01629875

DW_DWP450001

Details and patient eligibility

About

The purpose of this study was to observe Efficacy and safety of DWP450 compared with Botox in moderate to severe glabellar line patients.

Enrollment: 268 estimated patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

268 participants in 2 patient groups

DWP450

Experimental group

Treatment:

Drug: Generic equivalent of Clostridium Botulinum A Toxin

Botox

Active Comparator group

Treatment:

Drug: Botox (Clostridium Botulinum A Toxin)